Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept versus ranibizumab for wet age-related macular degeneration
ChiCTR-OPC-17013023Phase 4Not yet recruiting
- Sponsor
- Guizhou Provincial People's Hospital
- Start
- Nov 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept and ranibizumab in exudative macular degeneration (2 arms), sponsored by Guizhou Provincial People's Hospital. Primary endpoints: Best-corrected visual acuity, Quality of life and 1 more. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
conberceptranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR-OPC-17013023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013023.